Testing the mettle of PBT2 for Alzheimer's disease

The Lancet Neurology

Volumn 7, Issue 9, 2008, Pages 762-763

  Relkin, Norman R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLIOQUINOL; PBT 2; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHELATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; NEUROPSYCHOLOGICAL TEST; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLIOQUINOL; HUMANS; IONOPHORES; METALS; PEPTIDE FRAGMENTS; QUINOLINES;

EID: 48949096186     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70168-6     Document Type: Letter

References (3)

1. Lannfelt L., Blennow K., Zetterberg H., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 8 (2008) 779-786
2. Adlard P.A., Cherny R.A., Finkelstein D.I., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59 (2008) 43-55
3. Ritchie C., Bush A.I., Mackinnon A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691